Home/Pipeline/dNerva Lung Denervation System / Targeted Lung Denervation (TLD)

dNerva Lung Denervation System / Targeted Lung Denervation (TLD)

Chronic Obstructive Pulmonary Disease (COPD)

Phase 3Active

Key Facts

Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Phase 3
Status
Active
Company

About Nuvaira

Nuvaira is a clinical-stage medical device company pioneering a novel, interventional approach to treating COPD. Its core technology, the dNerva System, delivers radiofrequency (RF) ablation to pulmonary nerves via bronchoscopy, aiming to create a durable 'always-on' bronchodilator effect. The company is advancing this therapy through a robust clinical development program, with data suggesting improvements in lung function, reduction in exacerbations, and decreased breathlessness for a targeted COPD patient population. Nuvaira operates as a private entity, positioning its one-time procedural therapy as a potential complement or alternative to lifelong inhaled medications.

View full company profile

Therapeutic Areas

Other Chronic Obstructive Pulmonary Disease (COPD) Drugs